Education
About Us
Working with TipRanks
Follow Us
Nuvectis Pharma, Inc. (NVCT)
:NVCT
NVCT Analyst Ratings
Strong Buy
3 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
NVCT Stock 12 Month Forecast
Average Price Target
$15.67
▲(152.74% Upside)
| Highest Price Target$20.00 | Average Price Target$15.67 | Lowest Price Target$10.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
$10
Buy
61.29%
Upside
Reiterated
12/02/25
NXP900: A Promising New Standard in Post-TKI NSCLC TreatmentValuation and risks to price target achievement. We reiterate our Buy rating and $10 price target. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug's profile. We currently value Nuvectis on only the U.S. opportunities for 20% probability of success) and our projected initial risk-adjusted approved indications based on a biomarker-driven strategy. Moving forward, we believe significant upside potential exists based on: (1) rapid advancement through clinical development; (2) expansion to ex-U.S.
Maxim Group
$17
Buy
174.19%
Upside
Reiterated
11/17/25
Unknown Analyst
Roth MKMNot Ranked
Roth MKM
$20
Buy
222.58%
Upside
Reiterated
05/07/25
Laidlaw
$19
Buy
206.45%
Upside
Initiated
03/17/25
Lucid Capital
$18
Buy
190.32%
Upside
Initiated
02/26/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
$10
Buy
61.29%
Upside
Reiterated
12/02/25
NXP900: A Promising New Standard in Post-TKI NSCLC TreatmentValuation and risks to price target achievement. We reiterate our Buy rating and $10 price target. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug's profile. We currently value Nuvectis on only the U.S. opportunities for 20% probability of success) and our projected initial risk-adjusted approved indications based on a biomarker-driven strategy. Moving forward, we believe significant upside potential exists based on: (1) rapid advancement through clinical development; (2) expansion to ex-U.S.
Maxim Group
$17
Buy
174.19%
Upside
Reiterated
11/17/25
Unknown Analyst
Roth MKMNot Ranked
Roth MKM
$20
Buy
222.58%
Upside
Reiterated
05/07/25
Laidlaw
$19
Buy
206.45%
Upside
Initiated
03/17/25
Lucid Capital
$18
Buy
190.32%
Upside
Initiated
02/26/25
Best Analysts Covering Nuvectis Pharma
1 Month
xxx
Success Rate
3/5 ratings generated profit
Average Return
-0.96%
reiterated a xxx
rating 26 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 60.00% of your transactions generating a profit, with an average return of -0.96% per trade.
3 Months
xxx
Success Rate
6/10 ratings generated profit
Average Return
+8.11%
reiterated a xxx
rating 11 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +8.11% per trade.
1 Year
Success Rate
6/10 ratings generated profit
Average Return
+2.87%
reiterated a buy rating 11 days ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +2.87% per trade.
2 Years
xxx
Success Rate
7/10 ratings generated profit
Average Return
+6.66%
reiterated a xxx
rating 11 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 70.00% of your transactions generating a profit, with an average return of +6.66% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
NVCT Analyst Recommendation Trends
Rating
Jul 25
Aug 25
Oct 25
Nov 25
Dec 25
Strong Buy
9
7
6
6
7
Buy
0
2
2
2
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
9
9
8
8
7
Each month's total comprises the sum of three months' worth of ratings.
NVCT Financial Forecast
NVCT Stock Forecast FAQ
What is NVCT’s average 12-month price target, according to analysts?
Based on analyst ratings, Nuvectis Pharma, Inc.’s 12-month average price target is 15.67.
What is NVCT’s upside potential, based on the analysts’ average price target?
Nuvectis Pharma, Inc. has 152.74% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is NVCT a Buy, Sell or Hold?
Nuvectis Pharma, Inc. has a consensus rating of Strong Buy which is based on 3 buy ratings, 0 hold ratings and 0 sell ratings.
What is Nuvectis Pharma, Inc.’s price target?
The average price target for Nuvectis Pharma, Inc. is 15.67. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $20.00 ,the lowest forecast is $10.00. The average price target represents 152.74% Increase from the current price of $6.2.
The highest analyst price target is $20.00 ,the lowest forecast is $10.00. The average price target represents 152.74% Increase from the current price of $6.2.
What do analysts say about Nuvectis Pharma, Inc.?
Nuvectis Pharma, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.
How can I buy shares of NVCT?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.